Gene · 51755
Papers3,441
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,441
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| 3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer. | Nat Commun | 2026 | 41881987 | PubTator, text mining | PubMed |
| Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. | J Immunother Cancer | 2026 | 41881502 | PubTator, text mining | PubMed |
| p63 in skin homeostasis and disease: molecular mechanisms and therapeutic potentials. | Cell Death Discov | 2026 | 41876478 | PubTator, text mining | PubMed |
| GSK3i combinatorial treatments affect CDK4/6 and compensatory pathways in 3D preclinical models of pancreatic neuroendocrine tumors. | Biol Open | 2026 | 41873693 | PubTator, text mining | PubMed |
| Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer. | JCO Precis Oncol | 2026 | 41849730 | PubTator, text mining | PubMed |
| Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent Mechanism. | ACS Med Chem Lett | 2026 | 41847660 | PubTator, text mining | PubMed |
| Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol. | PLoS One | 2026 | 41838760 | PubTator, text mining | PubMed |
| Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial. | Target Oncol | 2026 | 41838385 | PubTator, text mining | PubMed |
| Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines. | Int J Mol Sci | 2026 | 41828359 | PubTator, text mining | PubMed |
| A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma. | Mol Cancer Ther | 2026 | 41814851 | PubTator, text mining | PubMed |
| Dual-Stimuli-Responsive Nanoplatform Delivering Molecular Glue CR8 for Synergistic CDK12 Degradation and Immunomodulatory Photothermal Therapy in TNBC. | ACS Appl Mater Interfaces | 2026 | 41810739 | PubTator, text mining | PubMed |
| Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. | Transl Androl Urol | 2026 | 41809806 | PubTator, text mining | PubMed |
| Cyclin-E/A/CDK1/2 Kinetic Landscapes Drive Cell Cycle Phase-Specific Progression and Guide Cyclin-E Degradation Strategy. | J Chem Inf Model | 2026 | 41801818 | PubTator, text mining | PubMed |
| Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report. | JTO Clin Res Rep | 2026 | 41798167 | PubTator, text mining | PubMed |
| Physalin A interferes with cell cycle in human oral squamous carcinoma cells via DNA topoisomerase II/ATM/ATR/Chk signaling for G2/M phase arrest. | Arch Biochem Biophys | 2026 | 41796887 | PubTator, text mining | PubMed |
| Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas. | J Immunother Cancer | 2026 | 41791790 | PubTator, text mining | PubMed |
| Prostate‑specific membrane antigen: Molecular functions and emerging roles as a therapeutic target (Review). | Mol Med Rep | 2026 | 41789574 | PubTator, text mining | PubMed |
| Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies. | Front Immunol | 2026 | 41766852 | PubTator, text mining | PubMed |
| Literature-driven extraction and computational prediction of causal statements linking genetic variants to biological processes, pathways and phenotypes. | Pac Symp Biocomput | 2026 | 41758181 | PubTator, text mining | PubMed |
| HIF1A transcriptionally activates CDKN1A to drive ferroptosis in skeletal muscle ischaemia-reperfusion injury. | J Orthop Translat | 2026 | 41757293 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51755/papers?page=4